Inflammatory bowel diseases
-
Inflamm. Bowel Dis. · Jun 2012
Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.
Salvinorin A (SA) has a potent inhibitory action on mouse gastrointestinal (GI) motility and ion transport, mediated primarily by kappa-opioid receptors (KOR). The aim of the present study was to characterize possible antiinflammatory and antinociceptive effects of SA in the GI tract of mice. ⋯ Our results suggest that the drugs based on the structure of SA have the potential to become valuable antiinflammatory or analgesic therapeutics for the treatment of GI diseases.
-
Inflamm. Bowel Dis. · Nov 2011
Development and validation of the Crohn's disease perceived work disability questionnaire.
No validated instruments have been developed to measure work disability in Crohn's disease (CD). The aim of our study was to develop and validate a CD perceived work disability questionnaire (CPWDQ). ⋯ The CPWDQ seems to be a valid, reliable tool for measuring subjective work disability in CD.
-
Inflamm. Bowel Dis. · Oct 2011
Comparative StudyExpression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease.
No serological marker currently exists to assess disease activity in patients with intestinal Behcet's disease (BD). We conducted this study to determine if the expression level of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) can be used as a biological marker to assess disease activity in intestinal BD. ⋯ Serum sTREM-1 levels were more highly correlated with disease activity than were CRP levels or ESR in patients with intestinal BD, suggesting that serum sTREM-1 level could be a potential marker for the assessment of disease activity of intestinal BD.
-
Inflamm. Bowel Dis. · Jul 2011
Letter Case ReportsUlcerative colitis after anesthesia with desflurane and sevoflurane.